Federal cannabis law moved in 2026 for the first time in more than fifty years, and the coverage since has mostly split into two camps. One treats the change as the end of federal prohibition. The other treats it as a technicality that changes nothing. Neither is accurate. What actually happened was narrower than the first reading and considerably more consequential than the second, particularly for the tax position of licensed operators and for anyone holding exposure to the sector. The details determine who benefits, who does not, and what is still genuinely unresolved. Here is what the order did, who it covers, and what remains open.
What the April Order Actually Did
On April 22, 2026, Acting Attorney General Todd Blanche signed a final order transferring two categories of marijuana from Schedule I to Schedule III of the Controlled Substances Act. The Department of Justice announced it the following day, and the order was published in the Federal Register on April 28 as AG Order No. 6754-2026, with that publication date controlling as the effective date.
The two categories are narrow and specific. The first is marijuana contained in a drug product approved by the Food and Drug Administration. The second is marijuana, including extracts and naturally derived delta-9-THC, that is subject to a qualifying state-issued license to manufacture, distribute or dispense for medical purposes.
The order followed a December 18, 2025 executive order directing the Attorney General to complete the rescheduling rulemaking as quickly as federal law allows. Blanche did not complete that rulemaking. He invoked separate authority to schedule substances in order to satisfy United States obligations under the 1961 Single Convention on Narcotic Drugs, which is why the order took effect without notice and comment, and why observers expect challenges under the Administrative Procedure Act.
The Two Tiers Nobody Explains Well
Everything outside those two categories stayed exactly where it was. Adult-use cannabis sold under a fully legal state program remains Schedule I. So does bulk marijuana, marijuana extract and delta-9 material used in the manufacture of FDA-approved products, and synthetically derived THC.
That produces a federal framework with two tiers running side by side over the same plant. A gram of flower can be Schedule III or Schedule I depending on which state license it was sold under, not on anything about the gram itself.
The order was also explicit about its own limits. It made no determination about federal legality more broadly, and it did not resolve the status of cannabis sold as food, as a dietary supplement, or as an unapproved drug. Operators seeking Schedule III treatment have to register with the DEA rather than receiving it automatically, and the order established an expedited pathway that leans on existing state licensing systems rather than building a parallel federal one.
Operators Sitting in Both Tiers at Once
The most immediate practical problem falls on a structure that is completely ordinary in the industry: a company holding both a medical and an adult-use license in the same state.
An operator holding both licenses, such as a Somerset dispensary in central New Jersey serving medical patients and adult-use customers from the same counter, now sits inside two federal classifications at once. The building is one building. The staff is one staff. The inventory system is one system. The federal exposure is two different things.
That splits work which used to be unified. Accounting has to separate activity by license type in a way it previously had no reason to. Recordkeeping obligations diverge, because Schedule III carries federal requirements around security, disposal and labeling that Schedule I activity does not. DEA registration applies to only part of the operation. For dual-licensed businesses, how to allocate shared costs between the two sides is not a bookkeeping preference. It determines the tax position.
The Tax Variable
Section 280E of the Internal Revenue Code disallows ordinary business deductions for any business trafficking in a Schedule I or Schedule II controlled substance. It has been the single largest federal cost of operating a licensed cannabis business, because it effectively taxes gross profit rather than net income.
Schedule III sits outside that provision. For qualifying state-licensed medical operators, the deduction disallowance falls away going forward, and that is the largest financial consequence attached to the entire proceeding. The order also encouraged the Treasury Secretary to consider retrospective relief for tax years in which an operator was already running under a state medical license, though encouragement is not the same as relief.
Two gaps remain. The order did not address state and local taxes, which are not directly affected by a federal scheduling change. And how 280E applies to a business selling both medical and adult-use product from one location is unresolved. The Justice Department’s announcement of the order sets out the scope of what was decided and, by omission, what was not.
What Has Not Been Decided
The broader question, whether cannabis generally should move to Schedule III, went to a separate expedited administrative hearing. It opened on June 29, 2026 and closed on July 15 after eleven days of testimony. Post-hearing briefs followed in August, and in its own final brief the DEA argued that marijuana no longer meets the statutory criteria for Schedule I.
The administrative law judge has not issued a recommendation. Once that recommendation lands, the DEA still has to act on it, and any resulting order would face its own round of litigation. Practitioners tracking the docket place a final answer somewhere in late 2026 or 2027, with no statutory deadline forcing the pace.
As of this writing in September 2026, adult-use cannabis remains Schedule I. Planning for the possibility of a broader change is reasonable. Building a budget that assumes it is not.
What a Customer Notices
Almost nothing, which is the honest answer and part of why the coverage has been so confused. Product on the shelf did not change. Prices did not fall on April 28. Purchase requirements did not move, because those are set by state law, and state law was untouched.
What changed sits behind the counter, in the tax treatment of one half of a dual-licensed business and in the federal registration status of operators who choose to pursue it. For anyone evaluating the sector rather than shopping in it, that back-office distinction is where the 2026 order actually matters, and where the decision still pending will matter considerably more.
